Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1998 August; 78(4): 528–533.
PMCID: PMC2063104

Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.


The purpose of this study was to evaluate in a phase I-II trial whether low doses of recombinant human interleukin 2 (rHuIL-2) over a prolonged period of time are safe and effective in eradicating or controlling minimal residual disease in children with neuroblastoma given high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). From January 1992 to July 1996, 17 consecutive patients, with either stage IV or relapsed neuroblastoma, were enrolled. Patients received rHuIL-2 after a median time interval (min-max) of 105 days (56-153) after HDCT and ASCT. The protocol consisted of 2 'priming' courses of rHuIL-2 at escalating doses administered intravenously at 72-h intervals, followed by 'maintenance' with 11 monthly and six bimonthly boosting 5-day courses administered subcutaneously on an outpatient basis. At April 1997, 7 out of the 17 patients had completed the treatment schedule, four had discontinued treatment because of toxicity and four because of relapse; the remaining two patients are still on treatment, having completed 15 courses. Expansion of T lymphocytes, together with an increase in both natural killer cells and in activated T lymphocytes was evidenced. After a median (min-max) follow-up time of 30 (16-64) months, 12 out of 17 patients are alive and well. Two patients relapsed and died 14 and 35 months after transplant. Three patients are alive after having relapsed at 41, 21 and 13 months. The actuarial 2-year event-free survival and overall survival are 67% and 92% respectively. Intermittent administration of low doses of rHuIL-2 given for a long period of time is well tolerated and seems capable of controlling minimal residual disease after HDCT and ASCT in children with high-risk neuroblastoma.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bilgrami S, Silva M, Cardoso A, Miller KB, Ascensao JL. Immunotherapy with autologous bone-marrow transplantation: rationale and results. Exp Hematol. 1994 Oct;22(11):1039–1050. [PubMed]
  • Dini G, Lanino E, Garaventa A, Rogers D, Dallorso S, Viscoli C, Castagnola E, Manno G, Brisigotti M, Rosanda C, et al. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol. 1991 Jun;9(6):962–969. [PubMed]
  • Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, Fidani P, Amici A, Helson L. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol. 1992 Aug;15(4):319–322. [PubMed]
  • Favrot MC, Floret D, Negrier S, Cochat P, Bouffet E, Zhou DC, Franks CR, Bijman T, Brunat-Mentigny M, Philip I, et al. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant. 1989 Sep;4(5):499–503. [PubMed]
  • Garaventa A, Rondelli R, Lanino E, Dallorso S, Dini G, Bonetti F, Arrighini A, Santoro N, Rossetti F, Miniero R, et al. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group. Bone Marrow Transplant. 1996 Jul;18(1):125–130. [PubMed]
  • Guarini A, Sanavio F, Novarino A, Gillio Tos A, Aglietta M, Foa R. Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors. Br J Haematol. 1991 Nov;79(3):451–456. [PubMed]
  • Hercend T, Meuer S, Reinherz EL, Schlossman SF, Ritz J. Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. J Immunol. 1982 Sep;129(3):1299–1305. [PubMed]
  • Higuchi CM, Thompson JA, Cox T, Lindgren CG, Buckner CD, Fefer A. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res. 1989 Oct 15;49(20):5509–5513. [PubMed]
  • Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol. 1985 Jul;135(1):242–246. [PubMed]
  • Main EK, Monos DS, Lampson LA. IFN-treated neuroblastoma cell lines remain resistant to T cell-mediated allo-killing, and susceptible to non-MHC-restricted cytotoxicity. J Immunol. 1988 Nov 1;141(9):2943–2950. [PubMed]
  • Martí F, Pardo N, Peiró M, Bertran E, Amill B, García J, Cubells J, Rueda F. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Exp Hematol. 1995 Dec;23(14):1445–1452. [PubMed]
  • Negrier S, Michon J, Floret D, Bouffet E, Gentet JC, Philip I, Cochat P, Stamm D, Costil J, Gaspard M, et al. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol. 1991 Aug;9(8):1363–1370. [PubMed]
  • Paciucci PA, Mandeli J, Oleksowicz L, Ameglio F, Holland JF. Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion. Am J Med. 1990 Sep;89(3):308–312. [PubMed]
  • Pardo N, Martí F, Fraga G, Illa J, Badell I, Peiró M, Bertran E, García J, Rueda F, Cubells J. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med Pediatr Oncol. 1996 Dec;27(6):534–539. [PubMed]
  • Seeger RC, Villablanca JG, Matthay KK, Harris R, Moss TJ, Feig SA, Selch M, Ramsay N, Reynolds CP. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res. 1991;366:527–533. [PubMed]
  • Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. 1989 Jan 1;49(1):235–240. [PubMed]
  • Valteau-Couanet D, Rubie H, Meresse V, Farace F, Brandely M, Hartmann O. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant. 1995 Oct;16(4):515–520. [PubMed]
  • Welte K, Ciobanu N, Moore MA, Gulati S, O'Reilly RJ, Mertelsmann R. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. Blood. 1984 Aug;64(2):380–385. [PubMed]
  • Zhang SR, Salup RR, Urias PE, Twilley TA, Talmadge JE, Herberman RB, Wiltrout RH. Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2. Cancer Immunol Immunother. 1986;21(1):19–25. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK